glp-1 and muscle mass Using receptor agonists for weight reduction in dystrophy patients Balancing weight and muscle loss

This peptide is of clinical interest in the context of muscle repair and recovery

sources: 1: Hong SY, Gil HW, Yang JO, Lee EY, Kim HK, Kim SH, Chung YH, Hwang SK, Lee ZW (2005)

Tirzepatide (GLP-1/GIP) Tirzepatide is a first-in-class dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist, providing synergistic metabolic effects for diabetes and obesity research

Common side effects include: Drowsiness: You might feel sleepy or fatigued

Its part of the incretin system that helps regulate blood sugar and metabolism

More recently, emerging data suggests semaglutide may be effective , with some observational studies reporting weight reductions that appear promising when used in post-bariatric populations experiencing weight regain, though comparative efficacy claims require further validation through controlled trials